-
Mashup Score: 2Project Facilitate: 5 Years of Progress, Outreach, and Service - 5 hour(s) ago
OCE Insights is developed for The ASCO Post by members of the Oncology Center of Excellence (OCE) at the FDA. In this installment, the authors discuss the past 5 years of Project Facilitate, an OCE in…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 0Meetings - The ASCO Post - 10 hour(s) ago
William Gradishar, MD, discusses advances in endocrine therapeutic options for patients with estrogen receptor–positive, HER2-negative breast cancer, in follow-up to his presentation at the Lynn Sage … Sunil S. Badve, MD, FRCPath, discusses research on tumor-infiltrating lymphocytes in the patient with breast cancer, based in part on his presentation at the Lynn Sage Breast Cancer Symposium, October… Charles E. Geyer, Jr, MD, FACP, discusses the management of patients with HER2-positive breast cancer
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Don't miss these insights from William Gradishar, MD; Sunil S. Badve, MD; Charles E. Geyer, Jr, MD; & Frederick Howard, MD with our coverage from @lynnsage Breast Cancer Symposium 2024. Watch all 4 videos here: https://t.co/lmU3z3DhJH #bcsm #breastcancer #oncology #LSBC24 https://t.co/PEFK2S5etk
-
-
Mashup Score: 0Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma - 6 day(s) ago
Maeve Lowery, MD, discusses the results of the phase II DUBHE-H-308 trial, which evaluated QL1706—a bifunctional antibody consisting of iparomlimab and tuvonralimab—plus bevacizumab and/or chemotherapy in the first-line treatment of advanced hepatocellular carcinoma (Abstract LBA38). Disclaimer: This video transcript has not been proofread or edited and may contain errors. This presentation by Dr. Shu and colleagues reports results of a phase II study in the first-line treatment of locally advanced or
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Maeve Lowery, MD, on a Novel Bifunctional Antibody in Advanced Hepatocellular Carcinoma https://t.co/iwE9qbmgfl #hpbcsm #LiverCancer #oncology #ESMO24 #CancerInstIRE
-
-
Mashup Score: 0
Josep M. Llovet, MD, PhD, presented the results of the LEAP-012 trial during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). In this brief summary, Dr. Llovet talks further about how management of hepatocellular carcinoma differs across stages. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr Josep Llovet: So hepatocellular carcinoma is a major health problem globally. Is the second cause of cancer-related death, and there are around 1
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Josep M. Llovet, MD, PhD, on Treatment Options in Hepatocellular Carcinoma https://t.co/w1P2ySlQQv #hpbcsm #livercancer #oncology #ESMO24 @IcahnMountSinai
-
-
Mashup Score: 6
In light of the landmark 5-year overall survival results from HIMALAYA, Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, discuss how to choose among the various doublet immunotherapy options for unresectable hepatocellular carcinoma. Disclaimer: This video transcript has not been proofread or edited and may contain errors. Ghassan Abou-Alfa: No doubt we’ re very grateful for the opportunity that we had at ESMO to present that data and
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Doublet Immunotherapy Options for Unresectable Hepatocellular Carcinoma https://t.co/JTaCEzw6ht #hpbcsm #LiverCancer #oncology#immunotherapy #ESMO24 @GABOUALFA @LorenzaRimassa
-
-
Mashup Score: 7Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib - 7 day(s) ago
Rachna T. Shroff, MD, MS, FASCO, was the discussant for a phase III trial presented at the ESMO Congress 2024 evaluating the efficacy and safety of anlotinib plus penpulimab vs sorafenib as first-line therapy for advanced hepatocellular carcinoma (Abstract LBA40). Disclaimer: This video transcript has not been proofread or edited and may contain errors. I’ m excited to discuss the results from the phase III APOLLO Study that was presented this year in Barcelona at ESMO 2024. This was a study done
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Rachna T. Shroff, MD, MS, FASCO, on Advanced Hepatocellular Carcinoma: Anlotinib Plus Penpulimab vs Sorafenib https://t.co/kRNHLYrXQ0 #hpbcsm #LiverCancer #ESMO24 @rachnatshroff @UAZCancer
-
-
Mashup Score: 11Genitourinary Cancer Expert Yüksel Ürün, MD, Shares His Career Journey and the Importance of Achieving a Work/Life Balance - 8 day(s) ago
In this installment of The ASCO Post’s Living a Full Life series, guest editor Jame Abraham, MD, FACP, spoke with medical oncologist Yüksel Ürün, MD, about his clinical and research career in oncology…
Source: ascopost.comCategories: General Medicine News, Hem/OncsTweet-
RT @BbaharK: 👏🏻👏🏻How lucky we are to have you as our mentor and greatest supporter! @DrYukselUrun 🧿 https://t.co/o6DRKeVWgK https://t.co/fo…
-
-
Mashup Score: 0Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE - 8 day(s) ago
Josep M. Llovet, MD, PhD, presented the results of the phase III LEAP-012 trial, which evaluated the addition of lenvatinib plus pembrolizumab to transarterial chemoembolization (TACE), during the Presidential Symposium I at the ESMO Congress 2024 (Abstract LBA3). Disclaimer: This video transcript has not been proofread or edited and may contain errors. Dr Josep Llovet: Hi. I am going to summarize the study, Phase III LEAP-012, that was aimed to compare lenva, pembrolizumab, and TACE, versus TACE, or
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Josep M. Llovet, MD, PhD, on Intermediate-Stage Hepatocellular Carcinoma: Addition of Lenvatinib Plus Pembrolizumab to TACE https://t.co/qTp59xcEno #hpbcsm #LiverCancer #oncology #ESMO24 @IcahnMountSinai
-
-
Mashup Score: 16
Ghassan K. Abou-Alfa, MD, MBA, FASCO, of Memorial Sloan Kettering Cancer Center, New York, and Lorenza Rimassa, MD, of Humanitas Cancer Center, Milan, discuss the 5-year overall survival results from the phase III HIMALAYA trial evaluating tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (Abstract 947MO). Disclaimer: This video transcript has not been proofread or edited and may contain errors. Ghassan Abou-Alfa: Dr. Rimassa, Lorenza, I mean excited times with the H IMALAYA study. As
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Ghassan K. Abou-Alfa, MD, MBA, FASCO, and Lorenza Rimassa, MD, on Unresectable Hepatocellular Carcinoma: 5-Year Overall Survival Results From the HIMALAYA Trial https://t.co/lCta4xlZFZ #hpbcsm #LiverCancer #oncology #immunotherapy #ESMO24 @GABOUALFA @LorenzaRimassa
-
-
Mashup Score: 4
Komal Jhaveri, MD, FACP, is an Associate Professor of Clinical Medicine at Weill Cornell Medical College and a Breast Medical Oncologist & Early Drug Development Specialist at Memorial Sloan Kettering Cancer Center in New York. In this video from The ASCO Post Newreels, Dr. Jhaveri shares a summary of her talk presented recently at the Chemotherapy Foundation Symposium. Dr. Jhaveri discusses important data about the activity of antibody-drug conjugates in patients with breast cancer, including breast
Source: ascopost.comCategories: General Medicine News, Oncologists1Tweet-
Komal Jhaveri, MD, FACP, on Antibody-Drug Conjugates in Breast Cancer https://t.co/GrCBPLhJS2 #bcsm #breastcancer #oncology @ChemotherapyFnd #CFS2024 #CFS24 @WeillCornell @MSKCancerCenter
-
Project Facilitate: 5 Years of Progress, Outreach, and Service - The ASCO Post https://t.co/f0asnGSUnY